All In Biotech

Drug Trial Radar · NCT07867262

A Study to Evaluate the Effects of GDC-4198 in Combination With Letrozole, Fulvestrant, or Giredestrant in Participants With Locally Advanced or Metastatic Hormone Receptor-Positive, HER2-Negatve Breast Cancer

A Phase Ib, Multicenter, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-4198 in Combination With Letrozole, Fulvestrant, or Giredestrant in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer Who Are Sensitive or Resistant to Endocrine Therapy

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 165 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

165

Planned (sponsor's estimate)

Start

Dec 15, 2026

Primary completion

Aug 15, 2030

Study completion Aug 15, 2030

Sponsor

Lead sponsor
Genentech, Inc.Roche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Oct 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will evaluate the safety, pharmacokinetics, and preliminary activity of GDC-4198 when given in combination with endocrine therapy (ET) (letrozole, fulvestrant, or giredestrant) as first-line treatment to participants with locally advanced or metastatic Hormone receptor (HR)-positive, Human epidermal growth factor receptor-2 (HER2)-negative breast cancer

Conditions

  • Advanced or Metastatic Breast Cancer

Interventions

  • GDC-4198Drug

    Participants will receive GDC-4198 as per the schedule described in the protocol.

  • FulvestrantDrug

    Participants will receive fulvestrant as per the schedule described in the protocol.

  • LetrozoleDrug

    Participants will receive letrozole as per the schedule described in the protocol.

  • GiredestrantDrug

    Participants will receive giredestrant as per the schedule described in the protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and Severity of Adverse Events (AEs)Time frame: Approximately 30 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.